HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT04846868

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Medication studyAges 18–50Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
Garden Grove, United States · La Habra, United States and 103 more locationsSee all locations and recruitment
Activities
Medication described in the protocol · Placebo comparator
Compensation
Payment and expense reimbursement have not been verified.
Study clarity

Study information

Study start dateStarted: September 8, 2021
Recruitment status
Completed
Enrollment listed in the registry
620
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, Canada, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT04846868
Official title
Show the full official title

A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-1)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Garden Grove, United States · La Habra, United States · San Diego, United States

102 more locations
  • Santa Ana, United States
  • Hartford, United States
  • Miami, United States
  • Atlanta, United States
  • Buffalo, United States
  • Staten Island, United States
  • Cincinnati, United States
  • North Canton, United States
  • Eugene, United States
  • Austin, United States
  • DeSoto, United States
  • Fort Worth, United States
  • Houston, United States
  • Everett, United States
  • Melbourne, Australia
  • Belo Horizonte, Brazil
  • Belo Horizonte,Minas Gerais, Brazil
  • Criciúma, Brazil
  • Curitiba, Brazil
  • Goiânia, Brazil
  • São José do Rio Preto, Brazil
  • São Paulo, Brazil
  • Calgary, Canada
  • Kelowna, Canada
  • Toronto, Canada
  • Baoding, China
  • Beijing, China
  • Changsha, China
  • Guangzhou, China
  • Guiyang, China
  • Jining, China
  • Kunming, China
  • Ningbo, China
  • Shanghai, China
  • Wuxi, China
  • Xinxiang, China
  • Barranquilla, Colombia
  • Bello, Colombia
  • Bogotá, Colombia
  • Pereira, Colombia
  • Bad Homburg, Germany
  • Berlin, Germany
  • Mannheim, Germany
  • Westerstede, Germany
  • Athens, Greece
  • Chaïdári, Greece
  • Haidari, Greece
  • Heraklion, Greece
  • Nea Kifissia, Greece
  • Thessaloniki, Greece
  • Brescia, Italy
  • Milan, Italy
  • Orbassano (TO), Italy
  • Siena, Italy
  • Aichi, Konan, Japan
  • Chiba, Ichikawa, Japan
  • Fukuoka, Fukuoka, Japan
  • Fukuoka, Omuta, Japan
  • Hokkaido, Obihiro, Japan
  • Hokkaido, Sapporo, Japan
  • Kanagawa, Kawasaki, Japan
  • Kanagawa, Sagamihara, Japan
  • Kanagawa, Yokohama, Japan
  • Kochi, Kochi, Japan
  • Kyoto, Maizuru, Japan
  • Miyagi, Sendai, Japan
  • Nagano, Matsumoto, Japan
  • Niigata, Niigata, Japan
  • Saga, Kanzaki-gun, Japan
  • Saitama, Iruma-gun, Japan
  • Saitama, Kumagaya, Japan
  • Saitama, Saitama, Japan
  • Tochigi, Shimotsuga-gun, Japan
  • Tokushima, Tokushima, Japan
  • Tokyo, Kodaira, Japan
  • Tokyo, Machida, Japan
  • Tokyo, Setagaya, Japan
  • Tokyo, Shinjuku-ku, Japan
  • Tokyo, Toshima-ku, Japan
  • Yamaguchi, Ube, Japan
  • Yamanashi, Chuo, Japan
  • Guadalajara, Mexico
  • Mexico City, Mexico
  • Mérida, Mexico
  • Monterrey, Mexico
  • Takpuna Auckland, New Zealand
  • Moss, Norway
  • Oslo, Norway
  • Iloilo City, Philippines
  • Manila, Philippines, Philippines
  • Bialystok, Poland
  • Lodz, Poland
  • Poznan, Poland
  • Warsaw, Poland
  • Zabrze, Poland
  • Helsingborg, Sweden
  • Uppsala, Sweden
  • Ankara, Türkiye
  • Istanbul, Türkiye
  • Izmir, Türkiye
  • Manisa, Türkiye
  • Türkiye
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Did this study involve medication?

Yes. The study involved medication, including Iclepertin and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me